Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Go back to Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 55.53 +0.83 (1.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.70 | 52 Week High | $77.12 | |||
| Open | $55.39 | 52 Week Low | $49.03 | |||
| Day High | $55.94 | P/E | 36.06 | |||
| Day Low | $54.96 | EPS | $1.54 | |||
| Volume | 13,246,395 | |||||
